Melatonin

Melatonin

Supplement Forms/Alternate Names:

N-Acetyl-5-Methoxytryptamine; 5-Methoxy-N-Acetyltryptamine

Introduction

Melatonin is a hormone made by the body that helps regulate sleep. It can be taken as a pill, powder, or extract. It can also be applied to the skin and injected into the bloodstream by a healthcare provider. Melatonin has been used to ease anxiety, improve sleep, and lower blood pressure.

Dosages

1 to 10 milligrams as needed

What Research Shows

Likely Effective

May Not Be Effective

Unlikely to Be Effective

Editorial process and description of evidence categories can be found at EBSCO NAT Editorial Process.

Safety Notes

It is likely safe to take melatonin in small doses for a short time, but headache and daytime drowsiness may happen. Not enough studies have been done to say whether it is safe to take for a long period. It is also not known whether it is safe to take by women who are pregnant, trying to become pregnant, or breastfeeding.

Interactions

Talk to your doctor about any supplements or therapy you would like to use. Some can interfere with treatment or make conditions worse, such as:

  • Melatonin contains lactose. People with problems digesting lactose should talk to their doctors before taking melatonin.
  • People who have liver problems, immune diseases, kidney problems, or neurological problems should talk to their doctor before taking melatonin.

References

A. Alzheimer Disease

A1. McCleery J, Cohen DA, et al. Pharmacotherapies for sleep disturbances in Alzheimer's disease. Cochrane Database Syst Rev. 2014 Mar 21;(3):CD009178.

A2. Xu J, Wang LL, et al. Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2015 Aug;30(5):439-447.

A3. McCleery J, Cohen DA, et al. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2016 Nov 16;11:CD009178.

A4. Zhang W, Chen XY, et al. Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials. Neurol Sci. 2016;37(1):57-65.

A5. Wang YY, Zheng W, et al. Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer’s disease. Int J Geriatr Psychiatry. 2017;32(1):50-57.

B. Anxiety

B1. Hansen MV, Halladin NL, et al. Melatonin for pre- and postoperative anxiety in adults. Cochrane Database Syst Rev. 2015;(4):CD009861.

C. Autism Spectrum Disorders

C1. Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol. 2011;53(9):783-792.

D. Cancer Treatment Support

D1. Seely D, Wu P, et al. Melatonin as adjuvant care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther. 2012;11(4):293-303.

D2. Wang YM, Jin BZ, et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol. 2012 May;69(5):1213-1220.

E. Delirium

E1. Siddiqi N, Harrison JK, Clegg A, Teale EA, Young J, Taylor J, Simpkins SA. Interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev. 2016 Mar 11;3:CD005563.

E2. Chen S, Shi L, et al. Exogenous Melatonin for Delirium Prevention: a Meta-analysis of Randomized Controlled Trials. Mol Neurobiol. 2016 Aug;53(6):4046-4053.

F. Depression

F1. Hansen MV, Danielsen AK, et al. The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2014 Nov;24(11):1719-1728.

G. Dysmenorrhea

G1. Pattanittum P, Kunyanone N, et al. Dietary supplements for dysmenorrhoea. Cochrane Database Syst Rev. 2016 Mar 22;3:CD002124.

H. Emergence Agitation After General Anesthesia

H1. Andersen LP, Werner MU, et al. A systematic review of peri-operative melatonin. Anaesthesia. 2014 Oct;69(10):1163-71.

H2. Mihara T, Nakamura N, et al. Effects of melatonin premedication to prevent emergence agitation after general anaesthesia in children: A systematic review and meta-analysis with trial sequential analysis. Eur J Anaesthesiol. 2015 Dec;32(12):862-871.

I. Epilepsy

I1. Brigo F, Igwe SC, et al. Melatonin as add-on treatment for epilepsy. Cochrane Database Syst Rev. 2016;(8):CD006967.

J. High Blood Pressure

J1. Grossman E, Laudon M, et al. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag. 2011;7:577-584.

J2. Hadi A, Ghaedi E, et al. Effects of Melatonin Supplementation On Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Horm Metab Res. 2019 Mar;51(3):157-164.

K. Jet Lag

K1. Tortorlo F, Farren F, et al. Is melatonin useful for jet lag? Medwave. 2015;15(3):e6343.

L. Metabolic Disorders

L1. Doosti-Irani A, Ostadohammadi V, et al. The Effects of Melatonin Supplementation on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Horm Metab Res. 2018;50(11):783-790.

M. Migraine

M1. Long R, ZhuY, et al. Therapeutic rold of melatonin in migraine prophylaxis: A systematic review. Medicine (Baltimore). 2019;98(3):e14099.

N. Neonatal Sepsis

N1. Henderson R, Kim S, et al. Use of melatonin as adjunctive therapy in neonatal sepsis: A systematic review and meta-analysis. Complement Ther Med. 2018 Aug;39:131-136.

O. Parkinson Disease

O1. Zhang W, Chen XY, et al. Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials. Neurol Sci. 2016;37(1):57-65.

P. Seasonal Affective Disorder

P1. Kaminski-Hartenthaler A, Nussbaumer B, et al. Melatonin and agomelatine for preventing seasonal affective disorder. Cochrane Database Syst Rev. 2015;(11):CD011271.

Q. Secondary Sleep Disorders

Q1. Li T, Jiang S, et al. Exogenous melatonin as a treatment for secondary sleep disorders: A systematic review and meta-analysis. Front Neuroendocrinol. 2019 Jan;52:22-28.

R. Sleep Disorders

R1. Ferracioli-Oda E, Qawasmi A, et al. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013 May 17;8(5):e63773.

R2. Auld F, Maschauer EL, et al. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev. 2017;34:10-22.

R3. Abdelgadir IS, Gordon MA, et al. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis. Arch Dis Child. 2018 Dec;103(12):1155-1162.

S. Sleep Disturbances

S1. Liira J, Verbeek JH, et al. Pharmacological interventions for sleepiness and sleep disturbances caused by shift work. Cochrane Database Syst Rev. 2014 Aug 12;(8):CD009776.

Last reviewed March 2020 by EBSCO NAT Review Board Eric Hurwitz, DC
Last Updated: 6/29/2020

EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.

This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.

To send comments or feedback to our Editorial Team regarding the content please email us at healthlibrarysupport@ebsco.com. Our Health Library Support team will respond to your email request within 2 business days.

Home |Terms and Conditions |Concerned About Privacy? |Accessibility |Careers |For Employers and Medical Plan Providers

You may also be looking for: CVS/pharmacy | MinuteClinic | Specialty Pharmacy | SilverScript | Accordant